

Harrie J M Gijzen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1446880/publications.pdf>

Version: 2024-02-01

24
papers

908
citations

567281

15
h-index

677142

22
g-index

25
all docs

25
docs citations

25
times ranked

1201
citing authors

#	ARTICLE	IF	CITATIONS
1	$\hat{\Gamma}^3$ -Secretase Modulators as Potential Disease Modifying Anti-Alzheimer's™s Drugs. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 669-698.	6.4	149
2	The evolution of amidine-based brain penetrant BACE1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2033-2045.	2.2	138
3	Tear gasses CN, CR, and CS are potent activators of the human TRPA1 receptor. <i>Toxicology and Applied Pharmacology</i> , 2008, 231, 150-156.	2.8	102
4	Analogues of Morphanthridine and the Tear Gas Dibenz[<i>b,f</i>][1,4]oxazepine (CR) as Extremely Potent Activators of the Human Transient Receptor Potential Ankyrin 1 (TRPA1) Channel. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 7011-7020.	6.4	82
5	Design and Synthesis of a Novel Series of Bicyclic Heterocycles As Potent $\hat{\Gamma}^3$ -Secretase Modulators. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9089-9106.	6.4	59
6	New evolutions in the BACE1 inhibitor field from 2014 to 2018. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 761-777.	2.2	57
7	Tricyclic 3,4-dihydropyrimidine-2-thione derivatives as potent TRPA1 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 797-800.	2.2	50
8	5-Sulfonyl-benzimidazoles as selective CB2 agonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2574-2579.	2.2	32
9	Rational Design of Novel 1,3-Oxazine Based $\hat{\Gamma}^2$ -Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust $\hat{\Gamma}^2$ Reduction in the Brain. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5122-5137.	6.4	29
10	Structure-Based Design of Selective $\hat{\Gamma}^2$ -Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 5080-5095.	6.4	29
11	Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine $\hat{\Gamma}^2$ -Secretase (BACE1) Inhibitors via Active Conformation Stabilization. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5525-5546.	6.4	28
12	-Secretase Modulators: Can We Combine Potency with Safety?. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-10.	2.0	27
13	5-Sulfonyl-benzimidazoles as selective CB2 agonists-Part 2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 547-552.	2.2	26
14	Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020). <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 25-52.	5.0	22
15	Evaluation of a Series of $\hat{\Gamma}^2$ -Secretase 1 Inhibitors Containing Novel Heteroaryl-Fused-Piperazine Amidine Warheads. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1159-1165.	2.8	20
16	Optimization of 1,4-Oxazine $\hat{\Gamma}^2$ -Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5292-5303.	6.4	15
17	Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective $\hat{\Gamma}^2$ -Secretase (BACE1) Inhibitors over BACE2. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3075-3085.	6.4	11
18	JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14175-14191.	6.4	10

#	ARTICLE	IF	CITATIONS
19	Trifluoromethyl Dihydrothiazine-Based β -Secretase (BACE1) Inhibitors with Robust Central Amyloid Reduction and Minimal Covalent Binding Burden. <i>ChemMedChem</i> , 2019, 14, 1894-1910.	3.2	8
20	Discovery of an Extremely Potent Thiazine-Based β -Secretase Inhibitor with Reduced Cardiovascular and Liver Toxicity at a Low Projected Human Dose. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9331-9337.	6.4	7
21	Discovery of Extremely Selective Fused Pyridine-Derived β -Site Amyloid Precursor Protein-Cleaving Enzyme (BACE1) Inhibitors with High In Vivo Efficacy through 10s Loop Interactions. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14165-14174.	6.4	4
22	A Brain-Penetrant and Bioavailable Pyrazolopiperazine BACE1 Inhibitor Elicits Sustained Reduction of Amyloid β In Vivo. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 76-83.	2.8	3
23	Discovery and Chemical Development of JNJ-50138803, a Clinical Candidate BACE1 Inhibitor. <i>ACS Symposium Series</i> , 2018, , 91-114.	0.5	0
24	Modulating physicochemical properties of tetrahydropyridine-2-amine BACE1 inhibitors with electron-withdrawing groups: A systematic study. <i>European Journal of Medicinal Chemistry</i> , 2022, 228, 114028.	5.5	0